TTOO250117C1500
- 0.12
- 0.000.00%
T2 Biosystems Newsroom
T2 Biosystems Price Target Raised to $5.00/Share From $3.00 by Canaccord Genuity
T2 Biosystems Analyst Ratings
CCORF Maintains T2 Biosystems(TTOO.US) With Hold Rating, Raises Target Price to $5
T2 Biosystems: Hold Rating Maintained Amid Growth Prospects and Profitability Concerns
T2 Biosystems Analyst Ratings
Alliance Global Partners Maintains Neutral on T2 Biosystems, Lowers Price Target to $0.07
T2 Biosystems Analyst Ratings
T2 Biosystems (TTOO) Receives a Hold From BTIG
Alliance Global Adjusts Price Target on T2 Biosystems to $1.50 From $2.20, Maintains Neutral Rating
T2 Biosystems Analyst Ratings
Alliance Global Partners Maintains Neutral on T2 Biosystems, Lowers Price Target to $1.5
BTIG Keeps Their Hold Rating on T2 Biosystems (TTOO)
Analysts Offer Insights on Healthcare Companies: T2 Biosystems (TTOO) and Axsome Therapeutics (AXSM)
T2 Biosystems Analyst Ratings
Canaccord Genuity Downgrades T2 Biosystems to Hold, Adjusts Price Target to $2.5
Analysts Offer Insights on Healthcare Companies: T2 Biosystems (TTOO), Poseida Therapeutics (PSTX) and COMPASS Pathways (CMPS)
BTIG Reaffirms Their Hold Rating on T2 Biosystems (TTOO)
T2 Biosystems Cut to Neutral From Buy by Alliance Global Partners
BTIG Downgrades T2 Biosystems to Neutral from Buy, Lowers Price Target to $0.14 From $0.65
T2 Biosystems Cut to Neutral From Buy by BTIG